We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Rheumatology

Journal Scan / Research · July 25, 2022

Low-Dose Benzbromarone vs Low-Dose Febuxostat for Patients With Gout With Renal Uric Acid Underexcretion

Arthritis & Rheumatology (Hoboken, N.J.)


Additional Info

Arthritis & Rheumatology (Hoboken, N.J.)
Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion
Arthritis Rheumatol 2022 Jul 07;[EPub Ahead of Print], F Yan, X Xue, J Lu, N Dalbeth, H Qi, Q Yu, C Wang, M Sun, L Cui, Z Liu, Y He, X Yuan, Y Chen, X Cheng, L Ma, H Li, A Ji, S Hu, Z Ran, R Terkeltaub, C Li

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading